SE0004782D0 - Blockeringsmedel - Google Patents
BlockeringsmedelInfo
- Publication number
- SE0004782D0 SE0004782D0 SE0004782A SE0004782A SE0004782D0 SE 0004782 D0 SE0004782 D0 SE 0004782D0 SE 0004782 A SE0004782 A SE 0004782A SE 0004782 A SE0004782 A SE 0004782A SE 0004782 D0 SE0004782 D0 SE 0004782D0
- Authority
- SE
- Sweden
- Prior art keywords
- receptors
- cell
- specific
- pathogen
- compounds
- Prior art date
Links
- 239000002981 blocking agent Substances 0.000 title 1
- 102000005962 receptors Human genes 0.000 abstract 6
- 108020003175 receptors Proteins 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 244000052769 pathogen Species 0.000 abstract 4
- 230000001717 pathogenic effect Effects 0.000 abstract 3
- 108020001580 protein domains Proteins 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 230000008827 biological function Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 102000055277 human IL2 Human genes 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 102000006240 membrane receptors Human genes 0.000 abstract 1
- 108020004084 membrane receptors Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 244000000010 microbial pathogen Species 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0004782A SE0004782D0 (sv) | 2000-12-22 | 2000-12-22 | Blockeringsmedel |
| PCT/SE2001/002892 WO2002051869A1 (en) | 2000-12-22 | 2001-12-21 | Compounds comprising two or more identical protein domains interlinked by a peptide having such a length that each of the protein domains can interact simultaneously with its specific cell-surface structure and thereby block the function of the structure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0004782A SE0004782D0 (sv) | 2000-12-22 | 2000-12-22 | Blockeringsmedel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE0004782D0 true SE0004782D0 (sv) | 2000-12-22 |
Family
ID=20282362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE0004782A SE0004782D0 (sv) | 2000-12-22 | 2000-12-22 | Blockeringsmedel |
Country Status (2)
| Country | Link |
|---|---|
| SE (1) | SE0004782D0 (sv) |
| WO (1) | WO2002051869A1 (sv) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198952B2 (en) | 2008-09-22 | 2015-12-01 | The Brigham And Women's Hospital, Inc. | Compositions of and methods of using ligand dimers |
| US9029328B2 (en) | 2010-03-24 | 2015-05-12 | The Brigham And Women's Hospital, Inc. | Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands |
| WO2015056713A1 (ja) * | 2013-10-15 | 2015-04-23 | 国立大学法人東京大学 | ｃ－Ｍｅｔタンパク質アゴニスト |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993023550A2 (en) * | 1992-05-18 | 1993-11-25 | Genentech, Inc. | Activation of oligomerizing receptors by using fused receptor ligands |
| WO1997023639A1 (fr) * | 1995-12-22 | 1997-07-03 | Toray Industries, Inc. | Procede de production de proteines fusionnees biologiquement actives |
| US6187564B1 (en) * | 1997-07-10 | 2001-02-13 | Beth Israel Deaconess Medical Center | DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics |
| US6541669B1 (en) * | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
-
2000
- 2000-12-22 SE SE0004782A patent/SE0004782D0/sv unknown
-
2001
- 2001-12-21 WO PCT/SE2001/002892 patent/WO2002051869A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002051869A1 (en) | 2002-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200736273A (en) | Antibody glycosylation in the variable region | |
| TR199902372A2 (xx) | Sulfanilsilanlar. | |
| BR0111667A (pt) | Novos compostos | |
| AU2002305450A1 (en) | Proteomimetic compounds and methods | |
| EA200801170A1 (ru) | Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа | |
| DE69736995D1 (de) | Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle | |
| AU1922902A (en) | Novel means for the diagnosis and therapy of CTCL | |
| DE60123036D1 (de) | Anthrax-spezifisches antigen, impfstoffe die das antigen enthalten, anthrax-spezifische antikörper, und deren verwendungen | |
| DE69128543D1 (de) | Monoklonale antikörper der maus | |
| ATE516356T1 (de) | Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung | |
| DE60033528D1 (de) | Filtermembranen für physiologisch aktive substanzen | |
| ATE419277T1 (de) | Faktor-ixa-spezifische antikörper, die faktor- viiia-ähnliche wirkung zeigen | |
| ES2141086T3 (es) | Anticuerpos contra los ligando-analogos y su uso en los dosificados ligando-receptores. | |
| ITTO20020736A1 (it) | Filtro per leucociti e suo impiego per l'impoverimento di prodotti del sangue da leucociti. | |
| EA200200625A1 (ru) | Антипикорнавирусные соединения и композиции, их фармацевтическое применение и вещества для их синтеза | |
| WO1995011975A3 (en) | Retroviral superantigens, superantigen peptides, and methods of use | |
| ATE410514T1 (de) | Calciumbindende rekombinante antikörper gegen protein c | |
| BRPI0412699A (pt) | compostos e particulados hidrofóbicos e aplicações destes | |
| SE0004782D0 (sv) | Blockeringsmedel | |
| BRPI0416745A (pt) | novos compostos | |
| DE60032915D1 (de) | Gallium komplexe von 3-hydroxy-4-pyronen zur behandlung von durch intrazelluläre prokaryoten, dns- und retro-viren verursachten infektionen | |
| WO2003000733A3 (en) | Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis | |
| EP1766011A4 (en) | POLYPEPTIDE LIGANDS CONTAINING LINKS | |
| JP2004511237A5 (sv) | ||
| Crothers et al. | Origins of base specificity in actinomycin and other DNA ligands |